Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 12;11(2):e044420.
doi: 10.1136/bmjopen-2020-044420.

Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data

Samuel William David Merriel  1 , Suzanne Marie Ingle  2 , Margaret T May  2   3 , Richard M Martin  2   3
Affiliations

Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors for prostate cancer progression using primary care data

Samuel William David Merriel et al. BMJ Open. .

Abstract

Objectives: To confirm the association of previously reported prognostic factors with future progression of localised prostate cancer using primary care data and identify new potential prognostic factors for further assessment in prognostic model development and validation.

Design: Retrospective cohort study, employing Cox proportional hazards regression controlling for age, prostate specific antigen (PSA), and Gleason score, was stratified by diagnostic stage.

Setting: Primary care in England.

Participants: Males with localised prostate cancer diagnosedbetween 01/01/1987 and 31/12/2016 within the Clinical Practice ResearchDatalink database, with linked data from the National Cancer Registration andAnalysis Service and Office for National Statistics.

Primary and secondary outcomes: Primary outcome measure was prostate cancer mortality. Secondary outcome measures were all-cause mortality and commencing systemic therapy. Up-staging after diagnosis was not used as a secondary outcome owing to significant missing data.

Results: 10 901 men (mean age 74.38±9.03 years) with localised prostate cancer were followed up for a mean of 14.12 (±6.36) years. 2331 (21.38%) men underwent systemic therapy and 3450 (31.65%) died, including 1250 (11.47%) from prostate cancer. Factors associated with an increased risk of prostate cancer mortality included age; high PSA; current or ex-smoker; ischaemic heart disease; high C reactive protein; high ferritin; low haemoglobin; high blood glucose and low albumin.

Conclusions: This study identified several new potential prognostic factors for prostate cancer progression, as well as confirming some known prognostic factors, in an independent primary care data set. Further research is needed to develop and validate a prognostic model for prostate cancer progression.

Keywords: epidemiology; primary care; prostate disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Collin SM, Martin RM, Metcalfe C, et al. . Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008;9:445–52. 10.1016/S1470-2045(08)70104-9 - DOI - PMC - PubMed
    1. Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, 2013. http://globocan.iarc.fr
    1. Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr 2012;2012:146–51. 10.1093/jncimonographs/lgs031 - DOI - PMC - PubMed
    1. Donovan JL, Hamdy FC, Lane JA, et al. . Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425–37. 10.1056/NEJMoa1606221 - DOI - PMC - PubMed
    1. Hamdy FC, Donovan JL, Lane JA, et al. . 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–24. 10.1056/NEJMoa1606220 - DOI - PubMed

Publication types

Substances